Back to Search Start Over

IL-21 promotes the development of a CD73-positive Vγ9Vδ2 T cell regulatory population

Authors :
Jean-François Eliaou
Cécile Dejou
Virginie Lafont
Françoise Sanchez
Henri-Alexandre Michaud
Angeline Fages
Alexandre Zampieri
Laetitia They
Aurelie Gennetier
Nathalie Bonnefoy
Clément Barjon
Laurent Gros
Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM)
CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
CRLC Val d'Aurelle-Paul Lamarque
CRLCC Val d'Aurelle - Paul Lamarque
Institut de Génomique Fonctionnelle (IGF)
Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS)
Institut des Neurosciences de Montpellier - Déficits sensoriels et moteurs (INM)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
Institut de Génétique Moléculaire de Montpellier (IGMM)
Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)
CEntre Technique des Industries Mécaniques (CETIM)
CEntre Technique des Industries Mécaniques - Cetim (FRANCE)
Centre de génétique moléculaire (CGM)
Centre National de la Recherche Scientifique (CNRS)
Institut de génétique et biologie moléculaire et cellulaire (IGBMC)
Université Louis Pasteur - Strasbourg I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
St-Eloi University Hospital, Department of Oncology, 34000 Montpellier, France.
Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)
Institut des Neurosciences de Montpellier (INM)
Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)
Salvy-Córdoba, Nathalie
Source :
OncoImmunology, Vol 7, Iss 1 (2018), OncoImmunology, OncoImmunology, Taylor & Francis, 2017, 7 (1), pp.e1379642. ⟨10.1080/2162402X.2017.1379642⟩, OncoImmunology, 2017, 7 (1), pp.e1379642. ⟨10.1080/2162402X.2017.1379642⟩
Publication Year :
2018
Publisher :
Taylor & Francis Group, 2018.

Abstract

International audience; Vγ9Vδ2 T cells contribute to the immune response against many tumor types through their direct cytotoxic activity and capacity to regulate the biological functions of other immune cells, such as dendritic cells and IFN-γ-producing CD8+ T cells. However, their presence in the tumor microenvironment has also been associated with poor prognosis in breast, colon and pancreatic cancers. Additionally, recent studies demonstrated that cytokines can confer some plasticity to Vγ9Vδ2 T cells and promote their differentiation into cells with regulatory functions. Here, we demonstrated that activation of Vγ9Vδ2 T cells isolated from healthy donors and cultured in the presence of IL-21 favors the emergence of a subpopulation of Vγ9Vδ2 T cells that express the ectonucleotidase CD73 and inhibits T cell proliferation in a CD73/adenosine-dependent manner. This subpopulation produces IL-10 and IL-8 and displays lower effector functions and cytotoxic activity than CD73-negative Vγ9Vδ2 T cells. We also showed, in a syngeneic mouse tumor model, the existence of a tumor-infiltrating γδ T cell subpopulation that produces IL-10 and strongly expresses CD73. Moreover, maturation, IL-12 production and induction of antigen-specific T cell proliferation are impaired in DC co-cultured with IL-21-amplified Vγ9Vδ2 T cells. Altogether, these data indicate that IL-21 promotes Vγ9Vδ2 T cell regulatory functions by favoring the development of an immunosuppressive CD73+ subpopulation. Thus, when present in the tumor microenvironment, IL-21 might negatively impact γδ T cell anti-tumor functions.

Details

Language :
English
ISSN :
21624011 and 2162402X
Volume :
7
Issue :
1
Database :
OpenAIRE
Journal :
OncoImmunology
Accession number :
edsair.doi.dedup.....c4c3b72e8aa21636015cdf36afd230ab